Eli Lilly

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance

Eli Lilly has secured CDSCO marketing authorisation for donanemab, an amyloid-targeting therapy for adults with early symptomatic Alzheimer's

Eli Lilly invests $1B in India as Mounjaro succeeds, Hyderabad site to boost global supply and innovation

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets

Eli Lilly's weight-loss injection Mounjaro saw a 42% jump in September sales, touching Rs 80 crore as more patients shift to higher doses amid rising demand

The US pharma major to set up a manufacturing and supply hub in Hyderabad as part of a $1 billion investment aimed at boosting contract production in India

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Eli Lilly CEO Dave Ricks slammed the UK's strict drug pricing rules, warning that the country risks losing new medicines and investment unless changes are made to its rebate scheme

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management